Seeking Alpha

The FDA has granted a priority review to Celgene's (CELG +2.1%) Revlimid drug for patients with...

The FDA has granted a priority review to Celgene's (CELG +2.1%) Revlimid drug for patients with relapsed or refractory mantle cell lymphoma (MCL) after prior therapy. Revlimid, in combination with the steroid dexamethasone, has also won approval from China's State Food & Drug Administration for use in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|